Answers are grounded in this paper and cite their sources.
In August 2023, FDA approved Abrysvo for active immunization of pregnant individuals at 32 through 36 weeks gestational age to prevent lower respiratory tract disease (LRTD), including severe LRTD, caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. A pragmatic approach to narrow the interval of use of Abrysvo in pregnant individuals balanced benefits of vaccine effectiveness against potential risks to infant and mother.
No takes yet. Share an insight, caveat, or question.
Hong-Nguyen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: